Aldehyde Dehydrogenase 2 Genomics and Clinical Implications

Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme responsible for the oxidation of toxic aldehydes, notably acetaldehyde, into less harmful acids. Genetic variation in ALDH2, most prominently the Glu504Lys substitution, affects enzyme activity and underpins a spectrum of clinical phenotypes ranging from alcohol flushing and increased cancer susceptibility to metabolic and cardiovascular disorders. Population studies reveal that ALDH2 polymorphisms are prevalent in East Asian cohorts but also occur globally, with variable penetrance and disease associations. Reduced ALDH2 function exacerbates aldehyde‐induced protein adduct formation, mitochondrial dysfunction and oxidative stress, contributing to insulin resistance, fatty liver, fibrosis and impaired cardiac and renal performance. Conversely, pharmacological activation or gene‐delivery approaches to enhance ALDH2 activity show promise in ameliorating metabolic, inflammatory and fibrotic processes. A comprehensive genomic characterisation of ALDH2 variants, together with mechanistic insights into downstream pathways, is essential for stratified prevention strategies and novel therapeutic development.

Research from Nature Portfolio

Recent studies have demonstrated that the common Glu504Lys mutation markedly impairs ALDH2 activity in brown adipose tissue, leading to increased accumulation of lipid‐derived aldehydes and diminished mitochondrial respiration. In knock‐in mice bearing the human‐equivalent substitution, males showed heightened susceptibility to diet‐induced obesity, glucose intolerance and fatty liver due to reduced adaptive thermogenesis. Proteomic analysis revealed extensive 4-hydroxynonenal‐adducted proteins in fatty acid oxidation and electron transport chain complexes. Treatment with a selective, water-soluble ALDH2 activator restored enzyme function, reduced toxic aldehyde burden, improved energy expenditure and ameliorated metabolic parameters in both wild-type and mutant animals, highlighting the therapeutic potential of targeted ALDH2 activation.

Aldehyde Dehydrogenase 2 Genomics and Clinical Implications publication trend

The graph below shows the total number of articles in aldehyde dehydrogenase 2 genomics and clinical implications across all publications each year (not limited to Nature Index journals).

Technical terms

ALDH2: Mitochondrial enzyme catalysing the oxidation of aldehydes to carboxylic acids, crucial for detoxification of ethanol-derived and lipid peroxidation-derived aldehydes.

Missense mutation: A single nucleotide change in DNA that results in the substitution of one amino acid for another in the encoded protein, potentially altering enzyme structure and function.

Adaptive thermogenesis: The production of heat by brown adipose tissue in response to dietary excess or cold exposure, contributing to energy expenditure.

4-Hydroxynonenal: A cytotoxic aldehyde generated during lipid peroxidation that forms adducts with proteins and nucleic acids, impairing cellular functions.

Precision medicine: An approach to disease prevention and treatment that takes into account individual genetic, environmental and lifestyle factors to tailor interventions.

References

1. A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators. Nature Communications (2023).
2. Uncovering newly identified aldehyde dehydrogenase 2 genetic variants that lead to acetaldehyde accumulation after an alcohol challenge. Journal of Translational Medicine (2024).
3. Aldehyde dehydrogenase 2 preserves kidney function by countering acrolein-induced metabolic and mitochondrial dysfunction. JCI Insight (2024).
4. ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective. Journal of Biomedical Science (2017).